PubRank

J F Lassen

Author PubWeight™ 26.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med 2006 2.02
2 Evaluation of a near-patient test for C-reactive protein used in daily routine in primary healthcare by use of difference plots. Clin Chem 1997 1.67
3 [From science to clinical practice. Risk assessment in relation to treatment and prevention]. Ugeskr Laeger 1999 1.39
4 Near-patient test for C-reactive protein in general practice: assessment of clinical, organizational, and economic outcomes. Clin Chem 1999 1.28
5 Telemedicine used for remote prehospital diagnosing in patients suspected of acute myocardial infarction. J Intern Med 2002 1.23
6 HbAlc in an unselected population of 4438 people with type 2 diabetes in a Danish county. Scand J Prim Health Care 2001 1.11
7 Primary PCI as the preferred reperfusion therapy in STEMI: it is a matter of time. Heart 2009 1.04
8 Electromechanical mapping for detection of myocardial viability in patients with ischemic cardiomyopathy. Circulation 2001 0.96
9 Graphical interpretation of analytical data from comparison of a field method with reference method by use of difference plots. Clin Chem 1997 0.95
10 Use and validation of public data files for identification of the diabetic population in a Danish county. Dan Med Bull 2001 0.93
11 [Cross-sectional therapeutic programs--an example of a cooperative health care system. A review with comments]. Ugeskr Laeger 1998 0.89
12 C-reactive protein in general practice--how commonly is it used and why? Scand J Prim Health Care 1997 0.87
13 Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients. J Intern Med 2004 0.84
14 [Diagnostic value of C-reactive protein in bacterial infections. Review of the literature]. Ugeskr Laeger 1998 0.83
15 Biological variation of International Normalized Ratio for prothrombin times, and consequences in monitoring oral anticoagulant therapy: computer simulation of serial measurements with goal-setting for analytical quality. Clin Chem 1997 0.82
16 Myocardial infarction centres: the way forward. Heart 2005 0.82
17 Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998 0.81
18 Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation. Thromb Res 1998 0.80
19 Intravenous magnesium does not influence the activity of the coagulation cascade. Blood Coagul Fibrinolysis 2001 0.79
20 [Anticoagulant treatment]. Ugeskr Laeger 2000 0.78
21 Should patients with acute ST elevation MI be transferred for primary PCI? Heart 2004 0.78
22 From science to everyday clinical practice. Need for systematic evaluation of research findings. Scand J Prim Health Care 1999 0.78
23 A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med 2002 0.77
24 The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 1998 0.77
25 Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res 2000 0.75
26 Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction? Heart 2003 0.75
27 [Factor V Leiden mutation]. Ugeskr Laeger 1996 0.75
28 The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J Intern Med 2004 0.75
29 [Clostridium difficile infections]. Tidsskr Nor Laegeforen 1986 0.75
30 [Anticoagulant and thrombolytic therapy in deep venous thrombosis and pulmonary embolism]. Ugeskr Laeger 1995 0.75
31 [Resistance to activated protein C. The most common cause of familial thrombophilia]. Ugeskr Laeger 1996 0.75
32 [Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms]. Ugeskr Laeger 1990 0.75
33 [A non-immobilizing regimen following meniscal suturing]. Ugeskr Laeger 1989 0.75
34 [A new cause of accidents resulting from the use of air-powered tools]. Ugeskr Laeger 1989 0.75
35 [Insect stings. A prospective study of complications and injury mechanisms]. Ugeskr Laeger 1996 0.75
36 [Examination and treatment of dyslipemia after myocardial infarction--are the goals achieved?]. Ugeskr Laeger 2001 0.75
37 [Quality assurance]. Ugeskr Laeger 1995 0.75
38 [Ride-on rotary motor mowers--a new mechanism of injury. Home accidents]. Ugeskr Laeger 1989 0.75
39 [Differences in the use of C-reactive protein analysis and erythrocyte sedimentation in general practice and hospitals. Development from 1986 to 1995]. Ugeskr Laeger 1998 0.75
40 [Is the randomized controlled trial overvalued as a basis for clinical decision-making? A review with comments]. Ugeskr Laeger 1998 0.75
41 Left ventricular contractile function after distal protection in primary percutaneous coronary intervention: results from the Drug Elution and Distal Protection in ST-Elevation Myocardial Infarction trial. Int J Cardiol 2009 0.75
42 [Clostridium difficile infections]. Tidsskr Nor Laegeforen 1986 0.75
43 Pathophysiology of coronary thrombosis. Semin Interv Cardiol 2000 0.75